MKE Startup News featured UWMRF’s licensee Estrigenix Therapeutics

A few highlights from the article in MKE Startup News about UWM's researcher and co-founder of Estrigenix Therapeutics, Karyn Frick: About Dr. Frick Frick is a renowned neuroscientist who wears many hats. Beyond teaching, running a federally-funded research lab and co-directing the university’s new Neuroscience major, she...

Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023. Promentis is developing SXC-2023 and other compounds that engage System xc-, a central nervous system (CNS) target addressing glutamatergic imbalance and oxidative stress, to treat obsessive-compulsive and related disorders, substance-related and addictive disorders and other neuropsychiatric disorders. SXC-2023 has demonstrated a compelling profile across a range of non-clinical studies.